Bone morphogenetic protein (BMP) 6 is a critical regulator of follicular development that is expressed in mammalian oocytes and granulosa cells. Glial cell line-derived neurotrophic factor (GDNF) is an intraovarian neurotrophic factor that plays an essential role in regulating mammalian oocyte maturation. The aim of this study was to investigate the effect of BMP6 on the regulation of GDNF expression and the potential underlying mechanisms. We used an established immortalized human granulosa cell line (SVOG cells) and primary human granulosa-lutein (hGL) cells as in vitro cell models. Our results showed that BMP6 significantly downregulated the expression of GDNF in both SVOG and primary hGL cells. With dual inhibition approaches (kinase receptor inhibitor and small interfering RNA knockdown), our results showed that both activin receptor kinase-like (ALK) 2 and ALK3 are involved in BMP6-induced downregulation of GDNF. In addition, BMP6 induced the phosphorylation of Sma-and Mad-related protein (SMAD)1/5/8 and ERK1/2 but not AKT or p38. Among three downstream mediators, both SMAD1 and SMAD5 are involved in BMP6-induced downregulation of GDNF. Moreover, concomitant knockdown of endogenous SMAD4 and inhibition of ERK1/2 activity completely reversed BMP6-induced downregulation of GDNF, indicating that both SMAD and ERK1/2 signaling pathways are required for the regulatory effect of BMP6 on GDNF expression. Our findings suggest an additional role for an intrafollicular growth factor in regulating follicular function through paracrine interactions in human granulosa cells. (Endocrinology 159: 2926(Endocrinology 159: -2938(Endocrinology 159: , 2018 B one morphogenetic protein (BMP) 6 is a member of the TGF-b superfamily that is highly expressed in mammalian oocytes and granulosa cells (1, 2). This intraovarian paracrine factor plays an essential role in regulating the development of ovarian follicles and follicular functions (1, 2). Female mice with deletion of the Bmp6 gene have a phenotype of reduced ovulation rate and impaired oocyte quality and embryo implantation, leading to decreased litter size (3). In vitro studies in rats have shown that BMP6 attenuated FSH-induced cAMP activity and production of progesterone and its related steroidogenic enzymes, such as steroidogenic acute regulatory protein and the P450 side-chain cleavage enzyme (4). In human granulosa-lutein (hGL) cells, treatment with BMP6 increased the expression of anti-Müllerian hormone and FSH receptor, whereas it decreased the expression of steroidogenic acute regulatory protein (5). In human luteinized steroidogenic cells, BMP6 suppressed luteinization by decreasing the production of progesterone (6). In mouse gonadotrope LbT2 cells, BMP6 enhanced somatostatin analog-induced inhibitory effects on LH secretion by increasing cell responsiveness to somatostatin analogs (7). In the human corpus luteum, the expression of BMP6 was increased, which may act as a luteolysis mediator *Both Peter C. K. Leung and Rui-Zhi Liu contributed equally to this article. Abbreviations: ALK, activin receptor kinase-like; BMP, bone morphogenetic protein; GDNF, glial cell line-derived neurotrophic factor; hCG, human chorionic gonadotropin; hGL, human granulosa-lutein; IVF, in vitro fertilization; siRNA, small interfering RNA; SMAD, Sma-and Mad-related protein; TBST, Tris-buffered saline containing 0.05% Tween 20.
B
one morphogenetic protein (BMP) 6 is a member of the TGF-b superfamily that is highly expressed in mammalian oocytes and granulosa cells (1, 2) . This intraovarian paracrine factor plays an essential role in regulating the development of ovarian follicles and follicular functions (1, 2) . Female mice with deletion of the Bmp6 gene have a phenotype of reduced ovulation rate and impaired oocyte quality and embryo implantation, leading to decreased litter size (3) . In vitro studies in rats have shown that BMP6 attenuated FSH-induced cAMP activity and production of progesterone and its related steroidogenic enzymes, such as steroidogenic acute regulatory protein and the P450 side-chain cleavage enzyme (4) . In human granulosa-lutein (hGL) cells, treatment with BMP6 increased the expression of anti-Müllerian hormone and FSH receptor, whereas it decreased the expression of steroidogenic acute regulatory protein (5) . In human luteinized steroidogenic cells, BMP6 suppressed luteinization by decreasing the production of progesterone (6) . In mouse gonadotrope LbT2 cells, BMP6 enhanced somatostatin analog-induced inhibitory effects on LH secretion by increasing cell responsiveness to somatostatin analogs (7) . In the human corpus luteum, the expression of BMP6 was increased, which may act as a luteolysis mediator (6) . Taken together, these studies indicate that BMP6 is an essential intraovarian regulator of follicular functions.
BMP6 initiates its cellular function by binding to BMP receptors, which are expressed in mammalian granulosa cells from secondary, antral, and atretic follicles (8, 9) . Studies of the signal transduction pathway have revealed that BMPs initiate cellular action through binding to two types (types I and II) of serine/threonine kinase receptors (10) . Among the seven TGF-b type I receptors, activin receptor kinase-like (ALK) 2, ALK3, and ALK6 (also known as ACTR1A, BMPR1A, and BMPRIB, respectively) have been shown to bind BMP ligands and induce the phosphorylation of intracellular downstream mediators, receptor-regulated Sma-and Mad-related proteins (SMADs; i.e., R-SMADs, SMAD1/5/8) (10) . Once phosphorylated, these R-SMADs further associate with a common SMAD (i.e., SMAD4) and enter the nucleus in which the complex (often in association with other transcription factors) regulates the transcription of target genes (11) . Currently, despite the obvious importance and relevance of BMP6 in reproductive function, the corresponding ALKs that are required to mediate the biological effects of BMP6 in human granulosa cells remain poorly defined.
Glial cell line-derived neurotrophic factor (GDNF) belongs to the GDNF family of ligands, which is crucial for the development and maintenance of central and peripheral neurons and has been used to treat several neurodegenerative diseases (12) . Outside the nervous system, GDNF and its receptors are expressed in many tissues, including the ovaries (13) . Recent studies have indicated that GDNF plays an essential role in regulating maturation in both murine and porcine oocytes (14) (15) (16) . In particular, treatment with GDNF alone or in combination with other neurotrophic factors increases the total yield of mature oocytes and the production or quality of early embryos in cultured immature human oocytes (17, 18) .
Given that oocyte maturation is essential for ovulation and fertility, the regulation (and underlying molecular mechanism) of intrafollicular GDNF has been a critical subject in reproductive biology. During the periovulatory phase, the LH surge dramatically induces the expression and secretion of GDNF, which promotes the extrusion of the first polar body and cytoplasmic maturation of the oocyte (17) . In cultured human granulosa cells, treatment with human chorionic gonadotropin (hCG) alone or combined with FSH significantly increased mRNA levels of GDNF in vivo and in vitro (17) . With in situ hybridization analysis, studies have shown that BMP6 was first expressed in granulosa cells and oocytes of the early secondary follicles in rat ovaries (19) . The expression of BMP6 increases as the follicles grow and is maximal at the preantral follicles. Notably, BMP6 mRNA is not detectable in the granulosa cells of dominant follicles, indicating that the suppression of BMP6 gene activity may be required for the formation of dominant follicles (19) . Interestingly, treatment with hCG also significantly decreased BMP6 mRNA levels in hGL cells both in vivo and in vitro (6) . The dramatic spatiotemporal changes (negative correlations) of BMP6 in granulosa cells and oocytes were accompanied by the expression of GDNF in granulosa cells. These data led us to propose that oocyte-and granulosa cell-derived BMP6 can prevent premature oocyte maturation by downregulating the expression of GDNF before the time of ovulation. Therefore, we aimed to investigate the effect of BMP6 on the expression and production of GDNF as well as the potential underlying molecular mechanisms in hGL cells.
Materials and Methods

Cell culture
Primary hGL cells were obtained from patients undergoing in vitro fertilization (IVF). After approval was obtained from the University of British Columbia Research Ethics Board, all patients provided informed consent. Collected hGL cells were purified via density centrifugation from follicular aspirates as previously described (20) . This study used a nontumorigenic, immortalized human granulosa cell line, the SVOG cell, which was previously produced by simian virus 40 large T-antigen transfection of early luteal phase human granulosa cells obtained from patients undergoing IVF (21) . Because the immortalized SVOG cells were generated from primary hGL cells, they displayed biological responses to many specific treatments that are similar to the responses of primary hGL cells (22) (23) (24) (25) (26) . Cells were counted with a hemocytometer, and cell viability was assessed with a 0.04% trypan blue exclusion. Cells were seeded in six-well plates (2 to 4 3 10 5 cells per well) and cultured in DMEM/nutrient mixture F-12 Ham medium (DMEM/F-12; Sigma-Aldrich Corp, Oakville, ON) supplemented with 10% charcoal/dextran-treated fetal bovine serum (HyClone Laboratories Inc., Logan, UT), 100 U/mL of penicillin plus 100 mg/mL of streptomycin sulfate (Invitrogen, Life Technologies, Grand Island, NY) and 1X GlutaMAX (Invitrogen, Life Technologies). The medium was changed every other day in all experiments. Before being treated with growth factors, SVOG cells were cultured in serum-free medium for 24 hours.
Antibodies and reagents
A polyclonal rabbit anti-SMAD1/5/8 antibody (N-18; sc-6031-R; diluted at 1:1000; RRID: AB_785721) and a monoclonal mouse anti-a-Tubulin antibody (sc-23948; diluted at 1:2000; RRID: AB_628410) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). A monoclonal rabbit antiphospho-SMAD1/5/8 antibody (13820; diluted at 1:1000; RRID: AB_2493181), a polyclonal rabbit anti-SMAD4 antibody (9515; diluted at 1:1000; RRID: AB_2193344), a monoclonal mouse antiphospho-ERK1/2 antibody (Thr202/ Tyr204; 8544; diluted at 1:1000), a polyclonal rabbit anti-ERK1/2 antibody (9102; diluted at 1:1000; RRID: AB_ 330744), a polyclonal rabbit antiphospho-p38 antibody (Thr180/Tyr182; 9211; diluted at 1:1000; RRID: AB_331641), a polyclonal rabbit anti-p38 antibody (9212; diluted at 1:1000; RRID: AB_330713), a polyclonal rabbit anti-phospho-Akt antibody (9271; diluted at 1:1000; RRID: AB_329825), and a polyclonal rabbit anti-Akt antibody (9272; diluted at 1:1000; RRID: AB_329827) were obtained from Cell Signaling 
Real-time quantitative RT-PCR
Cells were washed with cold PBS, and total RNA was extracted by TRIzol Reagent (15596018; Thermo Fisher, Invitrogen, Wilmington, DE) according to the manufacturer's instructions. The synthesis of DNA from a total amount of 2 mg of RNA as templates via reverse transcription using random primers, deoxyribonucleotide triphosphate, and reverse transcription (Promega, Madison WI) produces cDNA. TaqMan gene expression assays for human GDNF, ACVR1 (ALK2), BMPR1A (ALK3), BMPR1B (ALK6), SMAD1, SMAD5, SMAD8, SMAD4, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Hs01931883_s1, Hs00153836_ m1, Hs01034913_g1, Hs01010965_m1, Hs01077084_m1, Hs00195437_m1, Hs00195441_m1, Hs00929647_m1, and Hs02758991_g1, respectively; Applied Biosystems, Foster City, CA) were performed in triplicate on corresponding cDNA samples. For each 20 mL of TaqMan reaction, 4 mL of cDNA was mixed with 5 mL of RNase-free water, 10 mL of 2X TaqMan gene expression master mix (Applied Biosystems), and 1 mL of 20X TaqMan gene expression assay. Quantitative PCR was performed on an Applied Biosystems 7300 Real-Time PCR System equipped with 96-well optical reaction plates. The PCR parameters for the reaction were 50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Three separate experiments were performed on different cultures, and each sample was assayed in triplicate. A mean value was used for the determination of mRNA levels by the comparative quantification cycle value Cq (2 -ΔΔCq ) method with GAPDH as the reference gene.
Western blot analysis
Cells were washed with cold PBS and lysed in lysis buffer (Cell Signaling Technology) containing protease inhibitor cocktail (Sigma-Aldrich). Extracts were centrifuged at 20,000g for 15 minutes at 4°C to remove cellular debris, and protein concentrations were quantified using the DC Protein Assay (Bio-Rad Laboratories, Richmond, CA). Equal amounts of protein were separated by 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes. The membranes were blocked for 1 hour in Tris-buffered saline containing 0.05% Tween 20 (TBST) and 5% nonfat dried milk and incubated overnight at 4°C with the relevant primary antibodies (diluted at 1:1000 in TBST with 5% nonfat dried milk). After washing, the membranes were incubated for 1 hour with a peroxidase-conjugated secondary antibody (diluted at 1:5000 in TBST with 5% nonfat dried milk). Immunoreactive bands were detected using enhanced chemiluminescence reagents or SuperSignal West Femto Chemiluminescence Substrate (Pierce, Rockford, IL) followed by exposure to CL-XPosure film (Thermo Fisher, Invitrogen). Membranes were stripped with stripping buffer at 50°C for 30 minutes and reprobed with a total SMAD1/ 5/8, a total ERK1/2, or an a-Tubulin antibody as a loading control. Films were scanned and quantified by densitometry using image software (Scion Corp., Frederick, MD).
Small interfering RNA transfection
To knock down specific genes, we performed transient knockdown assays with ON-TARGETplus Non-targeting Control Pool or separate ON-TARGETplus SMARTpools targeting ALK2, ALK3, ALK6, SMAD1, SMAD5, SMAD8, or SMAD4 (Dharmacon, Lafayette, CO). Cells were cultured to 50% confluence in antibiotic-free DMEM/F-12 medium containing 10% charcoal/dextran-treated fetal bovine serum and then transfected with 25 nM of small interfering RNA (siRNA) using Lipofectamine RNAiMAX (13778030; Invitrogen, Life Technologies) for 48 hours. A total of 25 nM of ON-TARGETplus Non-targeting Control Pool (siCtrl) was used as the transfection control. Knockdown efficiency for each target was confirmed by real-time quantitative RT-PCR or western blot analysis.
Measurement of GDNF
After specific treatments, cell lysis was assayed immediately or stored at 280°C until assayed. GDNF protein concentrations of the extracts in cell lysis were measured as per the manufacturer's instructions using a solid phase sandwich enzyme immunoassay kit (EHGDNF; Thermo Fisher, Invitrogen). The inter-and intra-assay coefficients of variation for this assay were ,10%, and the detection limit was 4 pg/mL. Each sample was measured in triplicate, and intracellular GDNF concentrations were normalized to total cellular protein content.
Statistical analysis
Results were analyzed by one-way ANOVA followed by Tukey multiple-comparison tests using PRISM software (GraphPad Software, San Diego, CA). Results are presented as the mean 6 SEM of at least three independent experiments and were considered significantly different from one another if P , 0.05.
Results
BMP6 downregulated the expression of GDNF in hGL cells
The serum levels of BMP6 in mice, bovine, and humans are 55.46 to 128.7 pg/mL, 2.75 to 8.14 ng/mL, and 0.5 to 2.75 ng/mL, respectively (27, 28) . On the basis of most granulosa cell culture-related studies, we chose the concentration levels of 1 to 100 ng/mL to conduct our in vitro study (2, 6, 29) . To investigate whether BMP6 downregulates the expression of GDNF, we treated SVOG cells with different concentrations of recombinant human BMP6 (BMP6) (1, 10, or 100 ng/mL) for 12 hours. The results showed that treatment with BMP6 for 12 hours decreased GDNF mRNA levels in a concentration-dependent manner (Fig. 1A) . In the canine ovary, BMP6 is expressed in the oocytes and cumulus cells of the developing follicles (30) . In addition, studies using immunohistochemistry have demonstrated that BMP6 protein is expressed in hGL cells and the corpus luteum (2, 6) . On the basis of a previous study showing that BMP6 decreased basal levels of estradiol in cultured hGL cells (2), we used 50 ng/mL as the treatment concentration of BMP6 to perform the following experiments. The time course studies following BMP6 (50 ng/mL) treatment revealed that GDNF mRNA levels began to decrease as early as 3 hours, and the suppressive effects persisted until 24 hours (Fig. 1B) . Moreover, the suppressive effects of BMP6 on GDNF protein levels were confirmed by an enzyme immunoassay and a western blot analysis. As shown in Fig. 1C , treatment with different concentrations (1, 10, or 100 ng/mL) of BMP6 for 24 hours decreased GDNF intracellular protein levels. Nonimmortalized primary hGL cells obtained from infertile patients undergoing IVF treatment were used to further confirm the regulation of GDNF by BMP6 in hGL cells. Consistent with the results from SVOG cells, treatment with different concentrations (1, 10, or 100 ng/mL) of BMP6 for 12 hours decreased GDNF mRNA levels in a concentration-dependent manner (Fig. 1D) .
Both ALK2 and ALK3 were involved in BMP6-induced downregulation of GDNF
The TGF-b type I receptors ALK2, ALK3, and ALK6 have been shown to mediate BMP6 function (8, 10) . To determine whether ALK2, ALK3, or ALK6 is required for BMP6-induced downregulation of GDNF, we pretreated SVOG cells with a vehicle control (dimethyl sulfoxide) or 5 mM of dorsomorphin (a specific inhibitor of ALK2/ ALK3/ALK6) (31) for 1 hour, followed by treatment with 50 ng/mL of BMP6 for an additional 12 hours. As shown in Fig. 2A , pretreatment with dorsomorphin completely reversed the BMP6-induced decrease in GDNF mRNA level. To further determine which BMP type I receptor mediates BMP6-induced GDNF downregulation, we performed transient knockdown with ALK2, ALK3, or ALK6 siRNA before treatment with BMP6. The knockdown efficiency of specific siRNA was evaluated using real-time quantitative RT-PCR, and the results showed that transfection with individual siRNA for 12 or 24 hours significantly and specifically downregulated mRNA levels of the target ALKs (Fig. 2B-2D) . Notably, single knockdown of either ALK2 or ALK3 (but not ALK6) partially reversed the BMP6-induced decrease in GDNF mRNA level (Fig. 2E) . Moreover, dual knockdown of ALK2 and ALK3 completely reversed the BMP6-induced decrease in GDNF mRNA level (Fig. 2F) , indicating that both ALK2 and ALK3 are involved in BMP6-induced downregulation of GDNF in hGL cells.
SMAD1 and SMAD5 were involved in BMP6-induced downregulation of GDNF
Similar to other BMPs, BMP6 has been shown to exert its function through the canonical SMAD1/5/8 pathway in many cell types (11) . To investigate whether BMP6 activates SMAD1/5/8 signaling in hGL cells, we treated SVOG cells with a vehicle control or 50 ng/mL of BMP6 for 30, 45, or 60 minutes, and the phosphorylated SMAD1/5/8 protein levels were examined using western blot analysis. As shown in Fig. 3A , BMP6 treatment increased the phosphorylated proteins of SMAD1/5/8 at all time points examined. In addition, pretreatment with 5 mM of dorsomorphin abolished the BMP6-induced increase in phosphorylated proteins of SMAD1/5/8 (Fig. 3B) . To further determine which SMAD mediates BMP6-induced GDNF downregulation, specific siRNA was used to transiently knock down each SMAD. As shown in Fig. 3C , knockdown efficiency revealed that transfection of SVOG cells with 25 nM of each SMAD alone (siSMAD1, siSMAD5, or siSMAD8) for 24 or 48 hours significantly and specifically decreased (up to 80% to 90%) the mRNA levels of the individual SMAD. Interestingly, single knockdown of each SMAD (SMAD1, SMAD5, or SMAD8) did not affect the BMP6-induced decrease in GDNF mRNA level (Fig. 3D) , whereas dual knockdown of SMAD1 and SMAD5 completely reversed the BMP6-induced decrease in GDNF mRNA level (Fig. 3E) , indicating that both SMAD1 and SMAD5 are required for BMP6-induced downregulation of GDNF in hGL cells.
SMAD4 was involved in BMP6-induced downregulation of GDNF
In the canonical SMAD signaling pathway, SMAD4 acts as a co-SMAD that mediates TGF-b superfamily memberinduced cellular action (10) . To further confirm the functional role of SMAD signaling in hGL cells, we used SMAD4 siRNA to knock down SMAD4. SVOG cells were transfected with control siRNA or siSMAD4 (25 nM) for 48 hours. The knockdown efficiency confirmed that siSMAD4 significantly downregulated both SMAD4 mRNA and protein levels ( Fig. 4A and 4B) . Notably, knockdown of SMAD4 for 48 hours partially reversed the suppressive effects of BMP6 on GDNF mRNA and protein levels ( Fig. 4C and 4D ).
ERK1/2 pathway was involved in BMP6-induced downregulation of GDNF
Apart from the canonical SMAD-dependent pathway, MAPK signaling pathways have been shown to mediate BMP-induced activity in human cells (32, 33) . Next, we examined the involvement of MEK-ERK signaling in BMP6-induced downregulation of GDNF in SVOG cells. As shown in Fig. 5A , 50 ng/mL of BMP6 immediately increased the phosphorylated protein levels of ERK1/2 at 10, 30, and 60 minutes after treatment, whereas BMP6 treatment did not affect the phosphorylated protein levels of AKT and p38 at any time point examined (Fig. 5B) . In addition, the BMP6-induced increase in phosphorylated protein level of ERK1/2 was completely abolished by pretreatment with two BMP type I receptor inhibitors, dorsomorphin and 4-[6-[4-(1-methylethoxy) phenyl] pyrazolo[1,5-a] pyrimidin-3-yl]-quinoline (Fig. 5C) . Importantly, the BMP6-induced decrease in GDNF mRNA level was partially reversed by pretreatment with the MEK-ERK inhibitor U0126 (10 mM) (Fig. 5D ), indicating that ERK1/2 signaling is involved in BMP6-induced downregulation of GDNF in hGL cells.
BMP6 downregulated GDNF expression via ALK2/3-mediated SMAD and ERK1/2 signaling pathways
Given that inhibition of ERK1/2 activity or knockdown of SMAD4 only partially reversed BMP6-induced downregulation of GDNF expression, we used dual inhibition approaches to investigate the underlying mechanism. Intriguingly, concomitant inhibition approaches using knockdown of SMAD4 and the addition of the ERK1/2 inhibitor U0126 completely reversed the BMP6-induced decrease in GDNF mRNA levels in SVOG cells (Fig. 6A) . Consistent with the results of mRNA, concomitant knockdown of SMAD4 and the addition of the ERK1/2 inhibitor U0126 completely reversed the BMP6-induced decrease in GDNF protein level (Fig. 6B) . These results indicate that both SMAD and ERK1/2 signaling pathways are required for BMP6-induced downregulation of GDNF in hGL cells.
Discussion
During the periovulatory stage, locally produced growth factors and the related intrafollicular signaling between the oocyte and its surrounding somatic cells are critical modulators in regulating cell differentiation and oocyte maturation (9, 34) . Emerging evidence suggests that intraovarian BMPs are putative luteinization inhibitors acting to control several follicular functions, including suppression of progesterone production and promotion of the survival and development of growing follicles, as well as the inhibition of cell-cell communication in granulosa cells (35) (36) (37) (38) (39) . In the current study, we demonstrated that the recombinant growth factor BMP6 downregulated the expression of GDNF by decreasing both mRNA and protein expression levels in hGL cells. Our findings suggest a paracrine mechanism by which an oocyte-or granulosa cell-derived BMP can regulate oocyte maturation by suppressing the production of an intrafollicular neurotropic factor. Such a mechanism may provide an additional regulatory control over locally produced growth factors. Given that GDNF is a well-known oocyte maturation stimulator, our results showing that BMP6 downregulated the expression of GDNF in human granulosa cells may imply a potential role for BMP6 in inhibiting oocyte maturation. Similar to our results, previous in vivo and in vitro studies in zebrafish demonstrated that another oocyte-derived TGF-b superfamily member (i.e., BMP15) can inhibit the premature development and maturation of oocytes (40, 41) . Specifically, incubation of fish ovarian follicles with antiserum against BMP15 increased oocyte maturation, whereas incubation with BMP15 suppressed hCG-and anti-Müllerian hormone-induced oocyte maturation (40, 41) . Interestingly, , siMAD1, siSMAD5 , or siSMAD8) for 48 h and then treated with 50 ng/mL of BMP6 for an additional 12 h. GDNF mRNA levels were examined using quantitative RT-PCR. (E) SVOG cells were transfected with 25 nM of siRNA (siCtrl, combined siMAD1 and siSMAD5, combined siSMAD1 and siSMAD8, or combined siSMAD5 and siSMAD8) for 48 h and then treated with 50 ng/mL of BMP6 for an additional 12 h. GDNF mRNA levels were examined using quantitative RT-PCR. Results are expressed as the mean 6 SEM of at least three independent experiments. Values without a common letter are significantly different (P , 0.05). B6, BMP6; Ctrl, control; p-SMAD1/5/8, phosphorylated SMAD1/5/8.
BMP6 is increasingly expressed in the preantral follicle, and BMP6 mRNA is not detectable in the granulosa cells of dominant follicles (19) . Therefore, we may speculate that BMP6 exerts regulatory effects on the early stage of growing follicles to prevent precocious oocyte maturation in humans, mostly by suppressing the expression of GDNF. In granulosa cells of the dominant follicle, the absence of BMP6 may lead to elevated GDNF expression, which enhances the maturation of the oocyte. In human nonstimulated granulosa cells isolated from in vitro maturation oocytes, treatment with hCG alone or combined with FSH significantly increased GDNF transcript levels (17) .
Outside the reproductive system, an important role of BMP signaling in regulating the expression of GDNF was demonstrated in several recent studies. In the developmental stage of the human urinary system, BMP4 modulates the interaction between the ureteric buds and metanephric mesenchyme by suppressing GDNFmediated signaling through a canonical SMAD signaling pathway (42, 43) . In the fetal development of the enteric nervous system, BMP2 and BMP4 promote differentiation of enteric neurons in the early stage and glia in the later stage by modulating cell responsiveness to GDNF (44) . Disruption of BMP signaling may cause dysfunction of the enteric nervous system, leading to defects in the gut (44) . Furthermore, an in vitro study showed that overexpression of BMP4 reversed multidrug resistance in glioblastoma through the downregulation of GDNF (45) . Taken together, previous research and our studies suggest a negative regulatory role of BMPs in controlling GDNF signaling in developmental biology.
A comprehensive understanding of the cellular and molecular mechanisms underlying BMP-mediated cellular action is a core pharmacological skill for developing novel therapeutic strategies. Despite the obviously important function of BMP6 in female fertility, the receptors responsible for mediating the physiological effects induced by BMP6 remain poorly determined. Studies have shown that BMP-induced activation of SMAD1/5/8 in many cell types is mediated by ALK2, ALK3, or ALK6 (8) . In this study, we used the specific BMP type I receptor (ALK2/3/6) inhibitor dorsomorphin to investigate which receptors are required for cellular effects of BMP6 in human granulosa cells. Our results showed that pretreatment with dorsomorphin reversed the effects of BMP6 on phosphorylation of SMAD1/5/8 and downregulation of GDNF. However, studies looking at the specificity of dorsomorphin profiled against a panel of various protein kinases (more than 100 protein kinases) have demonstrated that dorsomorphin inhibited a number of kinases (e.g., AMPK, ERK8, PHK, MNK1, MELK, HIPK2, Src, Lck, VEGF-R, PRK2) with similar or even greater potency than the BMP type I receptors (46, 47) . The specificity profile of dorsomorphin has been overlooked by all of the studies describing or employing it as a specific inhibitor of the BMP pathway (31, 48) . Thus, it has been recommended that dorsomorphin is not a selective inhibitor of the BMP pathway (46, 47) .
Considering the off-target effect of the inhibitor, we therefore used an siRNA targeting approach to precisely target specific ALKs. Individual knockdown of either ALK2 or ALK3 (but not ALK6) only partially reversed BMP6-induced downregulation of GDNF expression.
However, this suppressive effect was completely reversed by dual knockdown of ALK2 and ALK3, indicating that both ALK2 and ALK3 could be major physiological receptors for BMP6 in human granulosa cells. Consistent with our results, BMP6-induced activation of SMAD signaling in C2C12 cells (an immortalized mouse myoblast cell line) was inhibited by pretreatment with two type I receptor inhibitors, dorsomorphin (inhibitor of ALK2/3/6) and LDN-193189 (inhibitor of ALK2/3) (49). In the skeletal system, ALK2 is the principle BMP type I receptor for BMP6. The binding affinity of BMP6 to ALK2 is 20 times higher than that of BMP7 (sharing high homology with BMP6) to ALK2 (50) . However, BMP6 binds to ALK6, rather than to ALK2 or ALK3, in ROB-C26 cells (a mesenchymal progenitor cell line) (50) . Likewise, an in vitro study showed that BMP6 supported motoneuron survival by inhibiting the effect of GDNF via binding to BMPRII and ALK3 in cultured mouse motor neurons (51) . Collectively, all these studies suggest that the requirement of BMP type I receptor for BMP6 is celltype specific because different cells express differential subsets of BMP type I and II receptors for BMP6. Furthermore, different types of type II receptors may recruit different types of type I receptors into the BMP6-receptor complex. Upon binding to and activating type I receptor, BMPs induce the canonical SMAD-dependent pathway by phosphorylating R-SMADs, SMAD1, SMAD5, and SMAD8 (10) . In general, almost all studies regard SMAD1/5/8 as a whole to be the principle R-SMAD for the downstream signaling of BMPs, with a handful of studies investigating the individual roles of these SMADs. Using a targeted depletion inhibition approach, we demonstrated that SMAD1 and SMAD5 but not SMAD8 are the primary mediators of BMP6-induced cellular action in human granulosa cells. In different cell types, BMP6-induced cell function can be mediated by a differential combination of the phosphorylation of SMAD1/5/8. In the skeletal system, the downstream signaling of BMP6 is primarily mediated by SMAD5 (50) . In particular, BMP6 stimulates mainly the phosphorylation of SMAD5 and, to a lesser extent, SMAD1 but not SMAD8 in MC3T3-E1 (an osteoblast precursor cell line) and C2C12 cells (50) . In human Sertoli cells, BMP6-induced increases in cell proliferation and apoptosis are mediated by SMAD2 and SMAD3 (52) .
After phosphorylation, SMAD2/SMAD3 combine with a common SMAD, SMAD4, which translocates into the nucleus and coordinates with other transcription factors to regulate target gene expression (10) . Notably, we found that knockdown of SMAD4 only partially reversed BMP6-induced downregulation of GDNF expression. Because BMPs have been shown to play biological roles by activating a non-SMAD signaling pathway (53), we further examined other signaling that may mediate the suppressive effect induced by BMP6. Aside from SMAD signaling, our results showed that BMP6 could also activate ERK1/2 signaling. Furthermore, the BMP6-induced suppressive effect on GDNF expression was partially reversed by the addition of the ERK1/2 kinase inhibitor U0126, indicating that ERK1/2 signaling is involved in BMP6-induced cell action in human granulosa cells. Expectedly, using the combined knockdown of SMAD4 and the addition of the ERK1/2 inhibitor, we further confirmed that both SMAD and ERK1/2 signaling is required for the cellular action of BMP6 in human granulosa cells. Both of these mechanisms can concurrently contribute to the repression of GDNF induced by BMP6 in human granulosa cells. Collectively, our findings may suggest a possible molecular mechanism that SMAD1/5-SMAD4 interacts and forms a complex association with the ERK1/2 activity that represses the transcription of GDNF. Future studies addressing the interaction and cross talk of these two signaling pathways will be of great interest.
In summary, we have demonstrated a potentially physiological function of BMP6 that negatively regulates the expression of GDNF in hGL cells. Our results showed that treatment with BMP6 activated SMAD1/ 5/8 and ERK1/2 but not AKT or p38 signaling. In addition, with the use of dual inhibition approaches, our results indicate that both ALK2 and ALK3 mediated the activation of SMAD and ERK1/2 signaling that is required for the BMP6-induced downregulation of GDNF expression in human granulosa cells. These results provide important insights into molecular mechanisms that mediate the cellular action of BMP6 in the regulation of GDNF expression in human granulosa cells.
